Endocrine Abstracts

JOINT2875

Multiple sclerosis is a demyelinating disorder of the central nervous system of autoimmune etiology and pathophysiology. The disorder is managed by the administration of immunomodulating agents. It may be accompanied by disability. As multiple sclerosis impairs mobility, obesity may accompany the disease. Additionally, diabetes mellitus type 2 may emerge. The aim was to describe a cohort of patients with multiple sclerosis, obesity and diabetes mellitus type 2 who were managed by the administration of GLP-1 receptor agonists. A cohort of 5 patients (4 female and 1 male), aged 35-55 years, is described who were followed up for multiple sclerosis. Patients were obese, BMI 31-39. Additionally, the presence of diabetes mellitus type 2 was diagnosed in 3 of the patients. GLP-1 receptor agonists were administered to this group of patients once weekly. Weight loss was noted after 6 months in this group of patients, weight loss ranging from 1.2 to 6.7 kg. GLP-1 receptor agonist administration was continued. No adverse effects were noted, apart from nausea in one of the patients. Multiple sclerosis is an autoimmune disorder characterized by demyelination. The disease causes mobility limitation and may be accompanied by obesity. Appropriate and effective obesity treatment is crucial in this group of patients as it may facilitate mobility and may prevent disability deterioration. The administration of GLP-1 receptor agonists is a proper treatment modality for this patient group as it seems not to be accompanied by severe adverse effects. In addition, it induces weight loss and acts therapeutically as an antidiabetic agent.